Nanobiotix stock climbs nearly 6% and defies a falling CAC 40
The Parisian biotech is posting one of the strongest gains on the French market this Thursday, in a market nevertheless oriented downward. The stock is regaining its upward momentum after the decline recorded at the beginning of the week, settling well above its moving averages.
A surge of nearly 6% that propels Nanobiotix among the strongest gains of the SBF 120
Nanobiotix gains 5.89% to €36.68 in trading, in an unfavorable market context: the CAC 40 loses 0.99% and the SBF 120 falls 0.90%. This countertrend propels the stock among the strongest gains of the SBF 120, neck and neck with the top positions on today's leaderboard. The gain erases part of the weekly decline, with the seven-day performance remaining negative at -3.78%, but the stock shows a gain of 4.68% over one month and nearly 400% over one year, representing one of the most remarkable performances on the Paris market over this period.
The last place in the SBF 120 recorded Monday, August 24, a day of sharp decline at the beginning of the week, now belongs to the past. Against the backdrop of a VIX at 14.87 (down 3.75% in trading), the market is operating in a low volatility regime, which does not dampen the vigor of the stock today.
Technical momentum remains bullish, with a neutral RSI and significant divergence from moving averages
The Nanobiotix stock is trading well above its two main moving averages: the 20-day MA at €34.56 (gap of +6.13%) and the 50-day MA at €33.67 (gap of +8.94%). This positioning reflects a favorable chart structure, although the RSI at 51 remains in neutral territory, with no overbought signal at this stage. The next level to watch is the resistance at €38.12, approximately 4% above the current price, while the support at €31.28 offers a comfortable downside gap.
The MACD confirms the positive momentum, with its histogram remaining in positive territory. The first quarter 2026 results published on June 2 highlighted progress in clinical trials on JNJ-1900 (NBTXR3) among the opportunities identified by the company.
